Jan Pirnos
Overview
Explore the profile of Jan Pirnos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mocikova H, Janikova A, Sykorova A, Prochazka V, Pirnos J, Duras J, et al.
Ann Hematol
. 2024 Oct;
104(1):675-684.
PMID: 39352469
Patients with testicular lymphoma are at an increased risk of central nervous system (CNS) disease. Optimal strategy for CNS relapse prevention is unknown. We analyzed treatment strategies, cumulative incidence of...
2.
Prochazka V, Belada D, Janikova A, Benesova K, Mocikova H, Duras J, et al.
EJHaem
. 2022 Jul;
1(1):170-180.
PMID: 35847728
Twenty percent of patients with high-tumor-burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5...
3.
Pytlik R, Vackova B, Konirova E, Trnkova M, Blahovcova P, Pohlreich D, et al.
Bone Marrow Transplant
. 2020 Sep;
56(3):709-712.
PMID: 32884117
No abstract available.
4.
Janikova A, Michalka J, Bortlicek Z, Chloupkova R, Campr V, Kopalova N, et al.
Ann Hematol
. 2020 Jun;
99(7):1583-1594.
PMID: 32506244
Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients...
5.
Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, et al.
Ann Hematol
. 2019 May;
98(8):1961-1972.
PMID: 31065733
Peripheral T cell lymphomas (PTLs) have a globally poor prognosis. The CHOP regimen shows insufficient efficacy; first-line consolidation with autologous stem cell transplantation (auto-SCT) is a promising strategy but has...
6.
Belada D, Prochazka V, Janikova A, Campr V, Blahovcova P, Pytlik R, et al.
Leuk Res
. 2018 Sep;
73:29-38.
PMID: 30195062
The rituximab maintenance (RM) therapy for follicular lymphoma is effective and clinically well tolerated, however there is limited data regarding this from the elderly segment of the population. This analysis...
7.
Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova M, et al.
Ann Hematol
. 2018 Jan;
97(4):669-678.
PMID: 29318369
The aim of this study is to assess the incidence, risk factors, and outcome of biopsy-proven transformation in follicular lymphoma (FL) patients in the rituximab era. Transformation was analyzed in...
8.
Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova J, et al.
Leuk Lymphoma
. 2015 Aug;
57(5):1094-103.
PMID: 26293000
Rituximab maintenance (RM) improves time to progression (PFS) in advanced follicular lymphoma (FL), but the impact of various RM schedules remains unknown. This study performed a retrospective evaluation of RM...
9.
Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Belada D, et al.
Leuk Lymphoma
. 2014 Nov;
56(8):2350-6.
PMID: 25426666
Early-stage follicular lymphoma (FL) has traditionally been treated with involved-field radiotherapy (RT). Rituximab (R) is a low-toxic, efficient systemic therapy for FL, but there are no data about its clinical...
10.
Pytlik R, Belada D, Kubackova K, Vasova I, Kozak T, Pirnos J, et al.
Leuk Lymphoma
. 2014 Mar;
56(1):57-64.
PMID: 24628294
We have studied the feasibility and efficacy of intensified R-MegaCHOP-ESHAP-BEAM therapy in high-risk aggressive B-cell lymphomas. Altogether 105 patients (19-64 years) with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell...